First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD StudyEduardo Díaz‐Rubio, María José Safont, Purificación Martínez de Prado et al.|The Oncologist|2012Cited by 213
Circulating Tumor Cell Count Is a Prognostic Factor in Metastatic Colorectal Cancer Patients Receiving First-Line Chemotherapy Plus Bevacizumab: A Spanish Cooperative Group for the Treatment of Digestive Tumors StudyJavier Sastre, Eduardo Díaz‐Rubio, M.L. Maestro et al.|The Oncologist|2012Cited by 88
First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD StudyEduardo Díaz‐Rubio, Enrique Aranda, Auxiliadora Gómez‐España et al.|Unknown|2012Cited by 25
Abstract LB1-06: Primary results of SOLTI VALENTINE: neoadjuvant randomized phase II trial of HER3-DXd alone or in combination with letrozole for high-risk hormone receptor positive (HR+)/HER2-negative (neg) early breast cancer (EBC)Mafalda Oliveira, Aleix Prat, Tomás Pascual et al.|Clinical Cancer Research|2025Cited by 3